Evotec

Evotec, Padlock Therapeutics extend collaboration

Monday, January 12, 2015 02:32 PM

Evotec, a Germany-based drug discovery alliance and development partnership company, and Padlock Therapeutics, a private, Cambridge, Mass.-based biotechnology company dedicated to creating new medicines to treat destructive autoimmune diseases, have successfully completed an initial goal in a program focused on developing inhibitors of protein-arginine deiminases (PADs) and have further extended the collaboration that was first signed in January 2014.

More... »


Evotec, Sanofi to collaborate

Wednesday, December 3, 2014 12:55 PM

Evotec has entered into exclusive negotiations with Sanofi on a major multi-component strategic alliance over the next five years. The collaboration will comprise three major strategic initiatives all focused on improving innovation effectiveness in the drug discovery and preclinical development space.

More... »


Evotec partners to develop multiple sclerosis treatments

Tuesday, September 30, 2014 10:00 AM

Evotec, a German-based drug discovery alliance and development partnership company, has entered into three novel research projects for the treatment of multiple sclerosis (MS), supported by research funds from the German Federal Ministry of Education and Research (BMBF).

More... »

Evotec takes legal steps against Andromeda Biotech

Friday, September 19, 2014 01:26 PM

Evotec, a Germany-based drug discovery alliance and development partnership company, will take legal steps against Israel-based Andromeda Biotech to recover all Evotec claims and potential damages that result from recent incidents in relation to DiaPep277.

More... »

Evotec, CHDI Foundation extend ongoing Huntington's disease collaboration

Friday, September 12, 2014 01:00 PM

The CHDI Foundation, a U.S. privately-funded nonprofit biomedical research organization, has extended and restated its collaboration with Evotec, a drug discovery solutions company based in Germany, through 2017. The collaboration, which aims to find new treatments for Huntington's disease, an inherited neurodegenerative disorder, means CHDI will fund up to 52 full-time scientists at Evotec over the next three years.

More... »

Evotec acquires Euprotec to augment anti-infectives platform

Thursday, May 29, 2014 01:04 PM

Evotec has acquired Euprotec, a U.K.-based specialist CRO. With a comprehensive portfolio of assays and disease models, Euprotec supports anti-infective drug discovery and development programs through to late stage preclinical investigation and clinical proof-of-concept studies.

More... »

Evotec, Eternygen collaborate for novel metabolic disease therapy

Monday, May 12, 2014 12:19 PM

Evotec, a drug discovery alliance and development partnership company, and Eternygen, a Berlin-based, privately owned biopharmaceutical company, are collaborating to develop novel small molecule inhibitors against an Eternygen target to treat metabolic diseases using Evotec's technology platform and experience in drug discovery and preclinical development.

More... »

Evotec inks agreements with Debiopharm Group, Convergence

Monday, April 7, 2014 12:37 PM

Evotec, a drug discovery alliance and development partnership company, has formed a research collaboration and licensing deal with Debiopharm Group, a Swiss-based global biopharmaceutical group, to identify and develop novel compounds having the potential to treat multiple forms of solid tumors and leukemias with defined genetic alterations.

More... »

Evotec, Debiopharm Group to collaborate on new treatment for cancer

Thursday, April 3, 2014 10:55 AM

Evotec has formed a research collaboration and licensing deal with Debiopharm Group, a Swiss-based global biopharmaceutical group, to identify and develop novel compounds having the potential to treat multiple forms of solid tumors and leukemia’s with defined genetic alterations. Discovery and preclinical development efforts will be driven by Evotec, while Debiopharm will manage clinical development. Evotec will receive R&D funding and high double-digit total payments triggered by clinical, regulatory and commercial milestones, plus royalties on sales of resulting commercial products.

More... »

Evotec collaborates with Leukemia & Lymphoma Society

Wednesday, November 6, 2013 12:59 PM

Evotec has entered into an integrated research collaboration with the Leukemia & Lymphoma Society (LLS). Evotec will support one of LLS's Screen-to-Lead Programs (SLP).

More... »

CenterWatch Data Library
CWWeekly

January 26

2015 CRO outlook: M&As, IPOs, strategic partnerships and increased eClinical outsourcing expected to continue

IOM, industry stakeholders propose standards, guidelines for open sharing of clinical trial data

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January

All eyes on EMA’s adaptive licensing pilot
Sponsors could offer innovative drugs to patients 8 years sooner

Ice Bucket Challenge a boon for ALS research
Donations soar, but phenomenon difficult to replicate

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs